Introduction {#S1}
============

Amyotrophic lateral sclerosis (ALS, OMIM \#105400) is a fatal neurological disorder affecting motor neurons located in the frontal cortex, brainstem, and spinal cord ([@B28]). The disease typically begins as muscle weakness in a limb, or occasionally with changes in voice or difficulty swallowing, which progresses to generalized weakness and paralysis of respiratory muscles leading to death due to respiratory failure. Approximately 10% of all ALS cases have a family history of the disease, while the remaining 90% are sporadic. The incidence of ALS is estimated to be 2.1 new cases per 100,000 population per year ([@B25]), and approximately 6,000 people are newly diagnosed with ALS each year in the United States alone. The number of ALS cases around the world is increasing due to the aging of the global population ([@B8]). There are currently no effective treatments for ALS, except for edaravone, which reduces the decline in daily functioning, and riluzole, which prolongs patients' survival by a few months ([@B75]; [@B94]).

Frontotemporal degeneration (FTD) is one of the most common types of dementia in people under 65. FTD may be divided into three primary subtypes, namely behavioral variant, semantic dementia, and progressive non-fluent aphasia. Among these subtypes, behavioral variant FTD is the most commonly observed type of dementia associated with motor neuron disorders ([@B15]). The incidence of FTD is approximately 4.0 new cases per 100,000 population per year, with 40% of cases being familial ([@B90]). Similar to ALS and other neurological disorders, there is no effective treatment for FTD ([@B108]).

It is now recognized that ALS and FTD are two diseases that form a broad neurodegenerative continuum. One of the earliest hints of this overlap came from the clinical observation that both disorders can be present within the same family or even within the same individual. Cross-sectional studies performed over the last decade estimate that up to 50% of ALS patients develop cognitive impairment associated with FTD. Similarly, up to 30% of FTD patients develop motor dysfunction ([@B22]).

Considerable progress has been made in unraveling the genetics of ALS and FTD, and it is now clear that the genetics of these two neurodegenerative conditions overlap significantly. TARDBP, SQSTM1, VCP, FUS, TBK1, CHCHD10, and most importantly C9orf72, are the critical genetic players, and their discoveries have implicated autophagy, RNA processing, and vesicle and inclusion formation as the central pathways involved in these forms of neurodegeneration.

Here we provide a summary of the significant genes identified in these two intrinsically linked neurodegenerative diseases and highlight where cross-talk exists. We describe the genes in the order of their relevance to ALS/FTD overlap, ranging from genes that have been demonstrated to cause both clinically and neuropathologically confirmed ALS and FTD to genes where the cognitive or motor symptoms are reported in the literature but pathological confirmation in not yet available.

The genes described in this review, clinical phenotypes and pathways associated with them are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Key genes identified in ALS and FTD.

  **Gene**   **Locus**   **Neurological phenotypes**                                                                                             **Pathway**                                    **Main localization**
  ---------- ----------- ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------
  FUS        16p11.2     ALS, FTD, ALS (juvenile with BIs) ET, MND (lower), bvFTD?, PD?                                                          Nucleocytoplasmic transport/splicing           Nucleus
  TDP-43     1p36.22     ALS, FTD, ALS (flail arm variant), SNGP and chorea, MND                                                                 Nucleocytoplasmic transport/splicing           Nucleus
  CHCHD10    22q11.23    ALS, ALS/FTD, Mitochondrial myopathy (autosomal dominant)                                                               Mitochondrial dysfunction/Synaptic integrity   Mitochondrion, nucleus
  C9orf72    9p21.2      AD, ALS, FTD, ALS/FTD, BD, PD, Schizophrenia                                                                            Nucleocytoplasmic transport/splicing           Extracellular, nucleus, endosome, lysosome
  UBQLN2     Xp11.21     ALS, FTD, Neurodegeneration, X-linked                                                                                   Autophagy/Proteasome                           Cytosol, plasma membrane, nucleus
  TBK1       12q14.1     ALS, ALS/FTD, AD                                                                                                        Autophagy/inflammation                         Nucleus, cytosol, endosome, mitochondrion
  VCP        9p13.3      IBMPFD, ALS, IBMPFD and ALS, CMT2, HSP DMRV, Scapuloperoneal muscular dystrophy and dropped head fibers, AD?, Autism?   Autophagy/Mitochondrial function               Nucleus, endoplasmic reticulum, cytosol, extracellular, lysosome
  SQSTM1     5q35        PDB, ALS, FTD, AD, early onset ALS/FTD, NADGP                                                                           Autophagy                                      Nucleus, cytosol, lysosome, endoplasmic reticulum, endosome

IBMPFD, inclusion body myopathy with Paget disease and frontotemporal dementia; AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; HSP, hereditary spastic paraplegia; CMT2, charcot-marie-tooth disease, type 2; PDB, paget's disease of bone; PD, Parkinson disease; BD, bipolar disorder; MND, motor neuron disease; ET, essential tremor; Bis, basophilic inclusions; DMRV-Myopathy, rimmed vacuolar; NADGP, neurodegeneration, childhood onset with ataxia, dystonia and gaze palsy; SNGP, supranuclear gaze palsy.

Chromosome 9 Open Reading Frame 72 (C9Orf72) {#S2}
============================================

In 2011, a hexanucleotide repeat expansion within the C9orf72 gene located on chromosome 9p21 was identified as a significant genetic cause of both ALS and FTD ([@B33]; [@B92]). This repeat expansion is the most common genetic cause of ALS, FTD, and ALS/FTD responsible for ∼11% of all ALS and ∼13% of all FTD cases. This discovery demonstrated that there is a more considerable genetic overlap between ALS and FTD than had been previously estimated. The majority of C9orf72-related FTD cases manifest behavioral symptoms with a much smaller percentage presenting with semantic dementia or with progressive non-fluent aphasia. C9orf72 repeat expansions have also been implicated as rare causes of other neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, ataxia, corticobasal syndrome, Huntington disease-like syndrome, and Creutzfeldt--Jakob disease ([@B13]; [@B50]; [@B35]).

Several mechanisms have been proposed to explain how C9orf72 expansion causes neurological disease. These include ([@B28]) haploinsufficiency of C9orf72 protein ([@B33]; [@B92]; [@B25]; [@B100]; [@B99]) RNA toxicity due to accumulation of RNA containing the GGGGCC repeat in the brain and spinal cord ([@B33]; [@B92]; [@B8]; [@B9]) dipeptide repeat (DPR) protein toxicity arising from repeat-associated non-AUG translation occurring off the expansion ([@B75]; [@B74]; [@B44]) disruption of the nucleocytoplasmic transport ([@B43]; [@B59]; [@B125]). Although the data for each of these mechanisms are compelling, it is not yet clear which of them plays the dominant role in determining neurodegeneration. The possibility of multiple mechanisms, operating in either unison or sequentially to bring about neuronal death, cannot be discounted.

Various mouse models have been created to elucidate the pathogenic mechanism underlying C9orf72 neurodegeneration. Though informative, these models have failed to resolve the exact mechanism, as the available information bolsters all four modes of neurodegeneration. For example, mice lacking C9orf72 in neurons and glial cells did not display motor neuron degeneration or defects in motor function associated with ALS ([@B64]). BAC transgenic mice with expanded human C9orf72 hexanucleotide repeat that ranged between 100 and 1000 repeats developed RNA foci and dipeptide repeat proteins throughout the nervous system. However, there was no evidence of neurodegeneration or functional deficits ([@B84]; [@B88]). Mice with more than 450 GGGGCC repeats have mild hippocampal neuronal loss and display signs of age-dependent anxiety and impaired cognitive functioning ([@B57]).

More recent mouse models showed that that loss of C9orf72 in a gain-of-function C9ALS/FTD mouse model aggravates motor behavior deficits in a dose-dependent manner ([@B99]). Transgenic GFP-PR28 mice expressing arginine-rich poly(PR), the most toxic type of DPRs in neurons, did partially develop neuropathological features of C9FTD/ALS ([@B49]). Two other transgenic C9FTD/ALS mouse models demonstrated that poly(GR) affects translation and stress granule dynamics ([@B126]) and compromises mitochondrial function by binding Atp5a1 ([@B26]).

TAR DNA-Binding Protein 43 (TARDBP) {#S3}
===================================

Mutations in the TAR DNA-binding protein 43 (the gene that encodes the TDP-43 protein) were linked to ALS in 2008 ([@B102]). Before that, it was recognized that TDP-43 cytoplasmic and nuclear inclusions are characteristic of both ALS and FTD. In ALS, the cytoplasmic accumulation of TDP-43 is found in neurons and glia of the primary motor cortex, brainstem motor nuclei, and spinal cord ([@B16]; [@B73]). In FTD, the inclusions are observed in the neocortex and dentate granule cells of the hippocampus ([@B81]; [@B31]). TDP-43 mutations are the cause of ∼ 1% of all ALS cases. In contrast, an even smaller number of FTD cases arising from mutations in this gene have been described, despite the widespread presence of TDP-43 in FTD brains ([@B105]).

TDP-43 is a DNA and RNA binding protein involved in many aspects of RNA metabolism, including splicing, microRNA biogenesis, transcription, and stabilization of messenger RNA ([@B21]; [@B103]; [@B19]; [@B40]; [@B67]). Two contrasting mechanisms have been proposed to explain TDP-43 related neurodegeneration, namely ([@B28]) loss of function arising from sequestration of critical TDP-43 protein within cytoplasmic aggregates leading to nuclear depletion of TDP-43 ([@B25]; [@B76]; [@B93]) gain of function effect due to some inherent toxic property of the aggregates ([@B20]; [@B51]). However, the toxic role of aggregated TDP-43 in neurodegeneration is still under debate. Recent research has focused on the role of stress granules in the pathogenesis of TDP43-related ALS ([@B62]). TDP-43 mutations have also been reported to alter liquid drop formation, though the pathophysiological role of this *in vitro* epiphenomena remains unclear ([@B29]).

More than fifteen mouse models have been created in the last 2 years in an attempt to decipher the pathogenic roles of TDP-43 in autophagy, protein homeostasis, and clearance pathways involved in ALS and FTD. These rodent models showed that suppression of conditional TDP-43 transgene expression differentially affects early cognitive and social phenotypes in TDP-43 mice ([@B101]). In a TDP-43Q331K/Q331K knock-in mouse model of ALS-FTD, TDP-43 gains function due to impaired autoregulation ([@B121]). In TDP-43M337V and TDP-43G298S knock-in mice, mutant TDP-43 causes early stage dose-dependent motor neuron degeneration ([@B38]). Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of motor neuron degeneration ([@B42]). Mouse models have also provided insight into how mutations in this gene may be underlying frontotemporal dementia. A recent TDP-43Q331K mouse model manifested cognitive dysfunction in the absence of motor dysfunction. Pathological examination showed that normal localization of TDP-43 within the cell, but there was evidence of perturbed regulation of TDP-43 ([@B120], [@B121]).

Sequestosome-1 (SQSTM1) {#S4}
=======================

Mutations in Sequestosome-1 (SQSTM1) was initially discovered in patients with Paget's disease of bone ([@B69]) and linked to ALS and behavioral FTD in 2011 ([@B39]). SQSTM1 encodes p62, a multifunctional protein involved in a wide range of cellular functions, including apoptosis ([@B60]), NFKB1 signaling ([@B41]), ubiquitin-mediated autophagy ([@B124]; [@B47]; [@B85]), and transcription regulation ([@B91]). p62 is also a standard component of ubiquitin-containing inclusions in several neurological disorders, including ALS and FTD. More than 100 variants have been identified in SQSTM1, and cumulatively they account for ∼1% of all ALS and up to 3% of all FTD cases. Defective p62 is prone to forming aggregates. Individuals with SQSTM1 variants have p62-positive inclusions in the motor neurons if presenting with ALS, and in the hippocampus and cerebral neocortex if presenting with FTD ([@B5]; [@B107]).

Accumulation of SQSTM1 comes from disturbances in the selective autophagy pathway ([@B34]). However, the pathogenic mechanism that contributes to SQSTM1-related impaired autophagy and degradation remains poorly understood. Similar to TDP-43 and FUS, SQSTM1 goes through liquid-liquid phase separation. Recent research shows that cytoplasmic DAXX drives SQSTM1/p62 phase condensation, an essential step in the activation of Nrf2-mediated stress response ([@B123]). Polyubiquitin chain-induced p62 phase separation leads to the segregation of autophagic cargo ([@B52]; [@B104]).

To date, no. p62 mouse model has been created to study the direct effect of p62 mutations in ALS/FTD. However, many mouse models exist that demonstrate a relationship between p62 and other ALS genes. [@B77] previously reported that loss of SQSTM1 exacerbates disease phenotypes in SOD1H46R ALS mice. Following the initial report, the same authors demonstrated that SQSTM1 overexpression results in a significant increase in biochemically detectable insoluble SQSTM1 and poly-ubiquitinated proteins in the spinal cord of SQSTM1; SOD1H46R mice when compared to SOD1H46R mice. This observation suggests that overexpression of p62 in SOD1H46R mice accelerates disease onset by impairing the protein degradation pathways ([@B77]).

From the FTD perspective, apart from developing mature-onset obesity due to impaired glucose tolerance and insulin resistance, p62 knockout mice display significantly reduced life span and accelerated aging phenotypes. These mice develop cognitive impairment and anxiety, which are symptoms characteristic of human Alzheimer's disease ([@B66]).

Fused in Sarcoma (FUS) {#S5}
======================

Fused in sarcoma (FUS) is an RNA-binding protein that was linked to ALS in 2009 ([@B65]). Similar to TDP-43, FUS is involved in multiple aspects of RNA metabolism regulation, including alternative splicing, RNA translation, and transport ([@B65]; [@B114]). Mutations in FUS are responsible for ∼1% of all ALS. They are also occasionally observed in behavioral FTD cases. In addition to these phenotypes, abnormal aggregates of FUS, independently of their mutations, are present in other neurodegenerative diseases such as hereditary essential tremor, the polyglutamine diseases, and Parkinson's disease.

Amyotrophic lateral sclerosis and FTD related mutations are clustered in highly conserved regions of the gene and affect the protein nuclear localization signal (NLS). Similar to TDP-43, mutations in the FUS gene are predominantly found in ALS patients. A limited number of FUS mutations (p.P106L, p.Gly174-Gly175 deletion GG, p.M254V) have been described in FTD patients without concomitant ALS ([@B111]; [@B55]).

Two mechanisms were proposed to explain FUS-related neurodegeneration. First of all, there is the toxic gain-of-function in which nuclear FUS aggregates in cytoplasm and spreads in a prion-like manner through neuronal tissues ([@B7]). Second, the depletion of FUS from the nucleus may impair transcription, alternative splicing, and DNA repair ([@B98]). A reasonable amount of evidence supports both mechanisms, and different mechanisms may stand behind different FUS mutations ([@B56]; [@B3]). Liquid--liquid phase separation (LLPS) of FUS has emerged recently as an alternative mechanism for FUS-related neurodegeneration. It is now established that LLPS is modulated by universal cellular actors such as ATP and nucleic acids through enhancement and dissolution ([@B61]). Other recent FUS studies expanded on LLPS functions, mechanism, and transformation ([@B14]; [@B61]; [@B79]; [@B82]).

Multiple mouse models have been created in an attempt to identify the pathogenic roles of FUS in neurodegeneration. FUS knockout mice display behavioral abnormalities such as hyperactivity and reduced anxiety-related behavior. However, they do not develop motor neuron impairment, suggesting that the ablation of the FUS gene alone is insufficient to cause ALS ([@B63]). Transgenic mice overexpressing exogenous FUS with nuclear localization signal deletion (ΔNLS-FUS) under Thy1 neuron-specific promoter develop progressive ALS phenotypes associated with the formation of ubiquitin/p62-positive FUS aggregates, neuronal loss, and gliosis. In FusΔNLS/ΔNLS mice, truncation of the NLS region leads to mislocalization of FUS protein from the nucleus to the cytoplasm in spinal motor neurons and cortical neurons where it leads to apoptosis ([@B97]). Furthermore, both FusΔNLS/+mice and knock-in mice carrying another C-terminal frameshift mutation (FusΔ14/+) develop progressive motor neuron loss in heterozygosity, recapitulating the early stages of disease ([@B97]; [@B36]). More recent FUSR514G and FUSR521C transgenic mice models show that overriding the FUS autoregulation system triggers gain-of-function toxicity via an altered autophagy-lysosome pathway and impaired RNA metabolism ([@B53]; [@B71]).

Valosin Containing Protein (VCP) {#S6}
================================

Mutations in Valosin containing protein (VCP) was initially discovered as the cause of a clinical syndrome characterized by the triad of inclusion body myopathy, Paget's disease of bone, and frontotemporal dementia (IBMFTD) in 2004 ([@B116]). Mutations in this gene were subsequently identified as a cause of ALS, representing an early example of how genetic mutations in a single gene could underlie both ALS and FTD ([@B58]). To date, 72 autosomal dominant mutations have been discovered in this gene, more than 30 of which are reported in ALS or FTD cases (including behavioral FTD, semantic dementia, and progressive non-fluent aphasia) ([@B2]; [@B96]; [@B12]). Many of the reported VCP mutations are located on exon five within the N-terminal CDC48 domain, which is involved in ubiquitin-binding, meaning that mutations in this region may negatively affect the ubiquitin protein degradation pathway ([@B46]; [@B109]).

A recent study by [@B2] showed that VCP mutations are present in ∼9% of ALS, 4% of Parkinson's disease, and 2% of Alzheimer's disease patients. As of today, no definite correlation between the mutation type and the incidence of clinical features associated with VCP has been established ([@B2]; [@B89]).

Valosin Containing Protein encodes a member of the AAA-ATPase enzyme family with wide-ranging functions in cell division ([@B83]), DNA repair, ubiquitin-dependent protein degradation, and suppression of apoptosis ([@B83]). [@B72] provides evidence that mutations in VCP lead to mitochondrial uncoupling due to a reduced ADP/ATP translocation by adenine nucleotide translocase. Such deficiency in mitochondrial bioenergetics makes neurons especially vulnerable as they require more energy than other cell types ([@B72]).

Recent mouse models of VCP showed that activation of the NLRP3 inflammasome is associated with VCP protein myopathy. [@B80] reported a significant increase in the expression of NLRP3, Caspase 1, IL-1β, and IL-18 in the quadriceps of 12 and 24 months old VCPR155H/+heterozygous mice. Furthermore, a significant increase of IL-1β(+)F4/80(+)Ly6C(+) macrophages in the quadriceps and bones of the same mice were also observed and is positively correlated with high expression levels of TDP-43 and p62/SQSTM1 markers of VCP pathology and progressive muscle wasting ([@B80]).

Another recent discovery showed that VCP plays a vital role in the maintenance of lysosomal homeostasis and TFEB activity in differentiated skeletal muscle ([@B6]). [@B6] showed that selective inactivation of VCP in skeletal muscles of Myl1p-cre-vcp-/-mice, results in a necrotic myopathy with increased macroautophagic/autophagic proteins and damaged lysosomes. It was further demonstrated that the myofiber necrosis was preceded by the upregulation of LGALS3/Galectin-3, a marker of damaged lysosomes, and TFEB activation, suggesting early defects in the lysosomal system ([@B6]).

Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10 (CHCHD10) {#S7}
==================================================================

Coiled-coil-helix-coiled-coil-helix domain-containing protein 10 (CHCHD10) is a mitochondrial protein associated with ALS and FTD, including the behavioral and primary progressive aphasia subtypes of this form of dementia ([@B1]; [@B30]). The protein was discovered in 2014 by exome sequencing of a large French family affected by autosomal dominant FTD with or without ALS, cerebellar ataxia, and mitochondrial myopathy ([@B24]). At least 30 variants have since been reported, and they are concentrated on exon two of the gene encoding the non-structured N-terminal ([@B106]; [@B86]; [@B127]).

Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10 is a multifunctional protein involved in the regulation of mitochondrial metabolism, synthesis of respiratory chain components, and modulation of cell apoptosis ([@B127]). Perhaps not surprisingly, mutations in CHCHD10 lead to disassembly of the mitochondrial contact site complex, severe mitochondrial DNA repair deficiency after oxidative stress, disruption of oxygen consumption and ATP synthesis in cells, and disturbance of apoptotic mechanisms ([@B127]).

Recent data shows enrichment of CHCHD10 expression at the postsynaptic membrane of neuromuscular junctions ([@B11]; [@B127]; [@B122]). Deletion of CHCHD10 in skeletal muscle of HSA-CHCHD10-/- knockout mice results in motor defects and neurotransmission impairment, indicating that muscle CHCHD10 is required for normal neurotransmission between motoneurons and skeletal muscle fibers ([@B122]). Furthermore, an examination of HSA-CHCHD10-/- mice mitochondria under an electron microscope revealed a large quantity of large lysosome-like vesicles, indicating active mitochondria degradation and suggesting that CHCHD10 is required for mitochondria structure and ATP production ([@B23]; [@B122]).

Two groups independently developed CHCHD10S55L knock-in mice, representative of human CHCHD10 S59L mutation, and found that these mice developed progressive motor deficits, myopathy, cardiomyopathy, and died prematurely ([@B4]; [@B48]). Histological examination revealed that CHCHD10, together with its twin CHCHD2 forms aggregates resulting in abnormal organelle morphology and function. In contrast, knock out CHCHD10 mice containing a single adenine nucleotide insertion in exon two that results in a prematurely terminated protein, did not develop similar pathology, suggesting that tissue-specific toxic gain-of-function is the likely mechanism behind CHCHD10 S59L related neurodegeneration ([@B4]).

TANK-Binding Kinase 1 (TBK1) {#S8}
============================

TANK-binding kinase 1 (TBK1) gene was discovered in 2015 through the whole-exome sequencing analysis of a large case-control cohort ([@B27]; [@B45]). In 2016, a large genome-wide association study (GWAS) also identified the TBK1 gene on chromosome 12q14.2 as a risk locus for ALS, thus confirming the gene's association with motor neuron degeneration ([@B113]). TBK1 is a member of the IkB kinase family involved in autophagy, mitophagy, and innate immune signaling ([@B117]). The protein is highly expressed in neuronal cells of the cerebral cortex, hippocampus, and lateral ventricle ([@B110]). It also interacts with other genes implicated in ALS, such as OPTN and SQSTM1, to form TBK1 autophagic adaptor complex ([@B95]; [@B78]; [@B70]).

To date, more than 90 mutations have been discovered on TBK1. According to a recent meta-analysis study, TBK1 loss of function and missense mutations account for 1.0 and 1.8% in ALS/FTD patients, respectively ([@B68]). The majority of TBK1 mutations are loss of function that result in the deletion of the C-terminal domain responsible for interaction with adaptor proteins that regulate the cellular distribution of TBK1 and activation of downstream signaling pathways ([@B95]). Indeed, mutations appear to lead to a significant decrease in TBK1 expression at the mRNA and protein levels ([@B45]).

TANK-binding kinase 1 mutations are associated with bulbar onset ALS and fast progressing behavioral FTD ([@B45]). In ALS patients, TBK1 mutations are pathologically characterized by TDP-43 positive and p62 positive inclusions in motor neurons, as well as TDP-43 inclusions in the cortex. Similar to that observed in ALS, FTD patients, harboring TBK1 mutations is also characterized by TDP-43 inclusions in numerous brain regions and cytoplasmic p62 and ubiquitin-positive inclusions in glial cells ([@B112]).

Compelling evidence exists that loss-of-function is the pathological mechanism behind TBK1-related ALS and FTD ([@B32]; [@B68]; [@B118]). Germline deletion of TBK1 is lethal in embryonic mice suggesting that the protein plays a critical role in developmental homeostasis ([@B17]). More recent rodent models demonstrated that conditional neuron-specific knockout of Tbk1 in Tbk1fl/fl Nestin-Cre mice leads to the development of cognitive and motor dysfunction similar to ALS/FTD. Neuron-specific Tbk1 deletion induces morphological and biochemical alterations in neurons and glia such as abnormal dendrites, neurofibrillary tangles, reduced dendritic spine density, as well as cortical synapse loss. Furthermore, Tbk1 knockout impairs autophagy in motor neuron-like cells, while Tbk1 over-expression extends survival of ALS transgenic mice ([@B37]).

TANK-Binding Kinase 1 is a central regulator of selective autophagy and inflammatory responses via IFN type I signaling ([@B87]; [@B54]). Heterozygous deletion of the α-IFN receptor Ifnar1 significantly prolongs the life span of SOD1G93A ALS mice ([@B115]). In a 2019 study, [@B18] further elucidated on the connection between TBK1 and SOD1 in the mouse models. The group showed that at the early stage, heterozygous Tbk1 deletion impairs autophagy in motoneurons and prepones the clinical onset and muscular denervation in SOD1G93A/Tbk1 ± mice, while at the late disease stage, it significantly alleviates microglial neuroinflammation, decelerates disease progression, and extends mouse survival ([@B18]).

Summary {#S8.SS1}
-------

After several decades of research, it is now clear that the same genes can cause ALS and FTD. Mutations in C9orf72, TARDBP, FUS, TBK1, VCP, CHCHD10, and SQSTM1 are the most closely associated with both diseases. Clinically, the ALS phenotype is most commonly associated with the behavioral variant of FTD, with other subtypes of FTD involving language occurring less commonly. The pathophysiology underlying this observation is poorly understood.

Nevertheless, this overlap is not complete: SOD1, FUS, and TDP-43 variants are most commonly associated with ALS and are only rarely found in FTD patients. Similarly, GRN is linked to FTD, but not to ALS. Clinically, the ALS phenotype is most commonly associated with the behavioral variant of FTD, with other subtypes of FTD involving language occurring less commonly. The pathophysiology underlying this observation is poorly understood.

It is striking how the same pathways are implicated repeatedly in ALS and FTD. Both disorders characterized by defects in RNA processing, protein clearance by autophagy, vesicle trafficking, mitochondrial dysfunction, and impaired protein homeostasis. The genes described in this review are the key players in these pathways. TDP-43 and FUS are responsible for RNA regulation; SQSTM1, C9orf72, VCP, and TBK1 are involved in autophagy and vesicle dynamics; TDP-43, FUS, and SQSTM1 are common components of nuclear and cytoplasmic inclusions ([@B119]). Due to such significant genetic overlap between ALS and FTD, it is reasonable to look in FTD cases for mutations in ALS genes, and vice-versa.

The C9orf72 repeat expansion gives rise to a diverse range of inter-familial and intra-familial phenotypes, including age at disease onset, site of symptom onset, rate and pattern of progression, levels of cognitive impairment and motor neuron degeneration, as well as disease duration. This clinical heterogeneity likely indicates that both genetic and environmental factors play a significant role in the development and course of the disease. Environmental factors such as occupational exposure to heavy metals, toxic compounds, and extremely low-frequency electromagnetic frequencies have been previously reported to increase the risk of developing neurological disorders. Studies on personal habits revealed an increased risk of ALS among smokers, as well as an overall worse prognosis after disease onset. In contrast, alcohol consumption was associated with a reduced risk of ALS. Literature analysis of head trauma and the development of neurological disorders were inconclusive. More recently, advanced genetic analysis of a large genetic dataset implicated high cholesterol as driving the risk of ALS, as well as confirming an association with smoking and physical exercise ([@B10]).

Research shows that environmental factors can influence people's chances of developing ALS or FTD. Nevertheless, the studies were performed on case cohorts that were not genetically selected. Different sets of environmental factors may interact with different genes. Consequently, future genetic epidemiology efforts should focus on cohorts selected based on their underlying genetic risk. Studying such population-based cohorts that have been assiduously collected and phenotyped for clinical features, genetics, epigenetics, and environmental and lifestyle exposures will be essential to these efforts.
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